Chinese Patients With Chronic Hepatitis B Respond Better To Telbivudine Than Lamivudine

... Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and Novartis (NYSE: NVS) todayannounced new data that demonstrate telbivudine, an investigational oral,once-daily nucleoside analogue, provided significantly greater antiviral andclinical efficacy in Chinese patients with chronic hepatitis B (CHB) afterone-year of treatment when compared with a current standard of care,lamivudine... click link for more info. ...